Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Kadowaki, D
Dose may be increased to 7.2 mg subcutaneously once weekly on patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated
Researchers may consult the relevant literature from past trials to see how it has been dosed in past studies
Summary Keywords IBD, GLP-1, GLP-1 receptor agonists, diabetes, obesity Citation Migliorisi G, Gabbiadini R, Dal Buono A, Ferraris M, Privitera G, Petronio L, Bertoli P, Bezzio C and Armuzzi A (2025) GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Seek prompt medical review if you experience persistent vomiting, signs of dehydration, inability to maintain adequate oral intake, or symptoms such as unusual fatigue, muscle weakness, numbness or tingling, which may indicate nutritional deficiencies requiring investigation
US$ 22.34
US$ 22.53
US$ 27.90
US$ 20.41
US$ 27.64
